Estratest
Result: $16.5 million settlement
Year: 2010
Yarrington v. Solvay Pharmaceuticals, Inc.
In March 2010, the Court granted final approval to a $16.5 million settlement of a false advertising class action lawsuit against Solvay Pharmaceuticals. Lieff Cabraser served as Co-Lead Counsel, representing purchasers of Estratest – a hormone replacement drug.
The complaint alleged that Solvay deceptively marketed Estratest as an FDA-approved drug when in fact Estratest was not approved by the FDA. The settlement provided refunds to consumers for up to 30% of the purchase price paid for Estratest. In addition, $8 million of the settlement was allocated to fund programs and activities related to women’s health concerns at medical schools throughout the nation.
Civil Litigation News
Court Grants Final Approval to Settlement in Kona Coffee Class Action Advertising Fraud Litigation
U.S. District Judge Robert S. Lasnik of the Western District of Washington at Seattle has granted final approval to the latest and
Court Once Again Rules Against Volkswagen in Dutch Dieselgate Proceedings
Company must pay Consumer €4,440.00, Dutch Consumer Group – the Consumentenbond – Calls for Settlement Talks On Friday October 6, 2023, the
Mark Chalos Selected as Co-Lead Counsel for Plaintiffs in Generac Solar Power Systems Marketing Practice and Products Liability Litigation
The Generac Solar Energy Systems litigation focuses on allegations that energy tech giant Generac’s PWRECell System components are defective and potentially dangerous
